A Phase 2a, Open Label, Randomized, Interventional Study to Assess the Safety and Immunogenicity of Alternative Vaccination Regimens and Reduced Antigen Doses of RTS,S/AS01E Vaccine in Healthy Children Aged 5-60 Months in a Malaria-endemic Area
Latest Information Update: 01 Jul 2025
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Pharmacodynamics
- Sponsors GSK
Most Recent Events
- 01 Jul 2025 New trial record